Sudeep Pharma Limited (SUDEEPPHRM)
🎯 Key Takeaways
- Sudeep Pharma Limited is in a growth phase driven by specialty ingredients, international expansion, and capacity ramp-up, with management targeting 25-30% long-term CAGR. The company is transitioning from a domestic-focused entity to a globally integrated specialty chemical player, supported by new leadership and project execution.
- ⚠️ Geopolitical tensions and logistics delays pose near-term supply chain risks, particularly affecting input costs and export flows. Battery material in
📖 The Story
Sudeep Pharma Limited is in a growth phase driven by specialty ingredients, international expansion, and capacity ramp-up, with management targeting 25-30% long-term CAGR. The company is transitioning from a domestic-focused entity to a globally integrated specialty chemical player, supported by new leadership and project execution. Financial performance shows resilient margin discipline amid cost pressures, underpinning confidence in scalable growth.
📰 What's Happening
In Q1 FY27, Sudeep Pharma achieved 27% YoY revenue growth to INR158.3 crores, with EBITDA rising 25% YoY to INR54.9 crores and margin stable at 34.7% despite input cost inflation. Management highlighted robust export demand in Europe and North America, with bisglycinate positioned as a top 2-3 revenue contributor. Phase 1 of the SAM project is scheduled for commissioning in April 2027, and the company added Non-Executive Director Milin Mehta to its board on 26 June 2026. Export markets remain a key growth lever, and operational efficiency is being prioritized amid supply chain and geopolitical headwinds.
Source: Stock Announcements
🔮 Management Outlook & What's Next
Management projects sustained 25-30% long-term CAGR, underpinned by specialty ingredients, global expansion, and capacity additions. Phase 1 of the SAM project is on track for commissioning in April 2027, which is expected to enhance production capabilities and support higher-margin offerings. Bisglycinate is identified as a strategic growth driver, and export markets in Europe and North America are viewed as high-potential contributors. Margin discipline and working capital optimization remain central to financial management priorities.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Chemicals & Petrochemicals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Solar Industries India Limited | 1.57 L Cr | 132.3 | — | — | — |
| Pidilite Industries Limited | 1.49 L Cr | 75.7 | — | — | — |
| SRF Limited | 79,723 | 69.5 | — | — | — |
| Linde India Limited | 62,701 | 141.9 | — | — | — |
| Gujarat Fluorochemicals Limited | 40,793 | 89.6 | — | — | — |
| Navin Fluorine International Limited | 35,894 | 131.5 | — | — | — |
| Himadri Speciality Chemical Limited | 30,071 | 56.6 | — | — | — |
| Deepak Nitrite Limited | 24,911 | 33.3 | — | — | — |
| Atul Limited | 20,904 | 48.8 | — | — | — |
| Tata Chemicals Limited | 19,079 | -47.1 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
Geopolitical tensions and logistics delays pose near-term supply chain risks, particularly affecting input costs and export flows. Battery material inventory buildup introduces potential working capital pressure, which management is actively addressing. While export demand remains strong, concentration in European and North American markets increases exposure to global macroeconomic slowdowns or regulatory shifts. Margin discipline must be maintained amid persistent input cost inflation.
📋 Recent Filings
-
🔴 Financial Results 11 August 2026Sudeep Pharma reported 27% YoY revenue growth to INR158.3 crores in Q1 FY27, driven by strong performance in pharma, food, and nutrition segments, wit...
-
🟡 Board Meeting 6 August 2026Sudeep Pharma Limited corrected the attendee count for its August 4, 2026 AGM from 45 to 44 (5 promoter and 39 public shareholders) in a regulatory fi...
-
Announcement 5 August 2026Sudeep Pharma Limited announced that the audio recording of its earnings call held on August 5, 2026, is now available on its website, with a transcri...
-
Announcement 4 August 2026Sudeep Pharma Limited reported Q1 FY27 results with revenue rising 27% YoY to **₹158.3 crores**, EBITDA up 25% to **₹54.9 crores**, and PAT surging 30...
-
Announcement 27 July 2026Sudeep Pharma announced an earnings call on August 5, 2026, to discuss Q1FY27 results, inviting analysts and investors to review operational and finan...
-
🔴 Corporate Action 10 July 2026Sudeep Pharma announced a final dividend of ₹1.50 per share for FY 2025-26, with the record date set for 23 July 2026 to determine entitlement ahead o...
-
🟡 Board Meeting 26 June 2026Sudeep Pharma announced the appointment of Mr. Milin Mehta as a Non-Executive Non-Independent Director effective 26 June 2026, following shareholder a...
-
🟡 Board Meeting 26 June 2026Sudeep Pharma announced the appointment of Mr. Milin Mehta as an additional non-executive non-independent director effective 26 June 2026, pending sha...
-
🟡 Board Meeting 21 May 2026Sudeep Pharma Limited announced the outcome of its 21 May 2026 board meeting, approving audited standalone and consolidated financial results for the ...
-
Announcement 21 May 2026Sudeep Pharma Limited reported FY26 revenue of **₹642.3 crores**, up 16% YoY, with PAT rising to **₹174.3 crores** (27.1% margin) and EPS at **₹12.79*...
🧠 Analyst's Read
Sudeep Pharma is executing a clear growth strategy centered on specialty chemicals and global expansion, supported by improving financial performance and targeted capex. The key near-term catalyst is the April 2027 commissioning of the SAM project, which will test scalability and margin realization. Investors should monitor export order trends, bisglycinate adoption, and working capital improvements as indicators of execution progress.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-08-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when SUDEEPPHRM files new disclosures
Track SUDEEPPHRM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track SUDEEPPHRM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research